Skip to main content
Premium Trial:

Request an Annual Quote

Mark Emkjer New CEO of Accelrys, Steven Rash Heads Power3, David U Prichard Joins Invitrogen s Board, and Others

Mark Emkjer has become president and CEO of Accelrys, formerly Pharmacopeia, the company said last week. He was also elected to the company's board of directors. Emkjer had been Accelrys' president since the end of 2002. Previously, he was president and COO of Sunquest Information Systems. In connection with the spin-off of Pharmacopeia Drug Discovery, Joseph Mollica, Frank Baldino, James Marino, and Paul Bartlett have resigned from the Accelrys board and will serve on the board of PDD.


 

Steven Rash has become chairman and CEO of Power3 Medical Products, replacing Tim Novak, who resigned, the company said last week. Ira Goldknopf will become the company's CSO. Paul Gray has resigned as CFO, secretary, and treasurer and will be replaced soon, according to the company. The management changes occurred in connection with Power3's acquisition of proteomics company ProteEx of The Woodlands, Texas.


 

David U'Prichard has joined the board of directors of Invitrogen, and David McCarty has left the board after finishing his five-year rotation, the company said last week. U'Prichard is currently a venture partner with Apax Partners and president of Druid Consulting. Previously, he was CEO of 3-Dimentional Pharmaceuticals. U'Prichard holds a PhD in pharmacology from the University of Kansas and a bachelor degree in pharmacology from the University of Glasgow in Scotland.


 

Katherine Andrews-Cramer has become the director for business development, and Dave Oehler director for marketing and sales at Chicago-based Integrated Genomics, the company said last week. Andrews-Cramer joins the company from Argenta Discovery, where she was vice president for business development. She has a PhD in biochemistry from the University of Illinois at Urbana-Champaign and a BA in biology from Lake Forest College in Lake Forst, Ill. Oehler was most recently director of sales for MiraiBio, a Hitachi Software company. He holds a BA in human biology from Stanford University.


 

Karin Eastham has become executive vice president and chief operating officer of the Burnham Institute, the La Jolla, Calif.-based research center said on Monday. She will also join the institute's board of trustees. Eastham joins the Burnham Institute from Diversa, where she was senior vice president for finance, CFO, and secretary. She earned an MBA and a BS from Indiana University and is a certified public accountant.

The Scan

Not as High as Hoped

The Associated Press says initial results from a trial of CureVac's SARS-CoV-2 vaccine suggests low effectiveness in preventing COVID-19.

Finding Freshwater DNA

A new research project plans to use eDNA sampling to analyze freshwater rivers across the world, the Guardian reports.

Rise in Payments

Kaiser Health News investigates the rise of payments made by medical device companies to surgeons that could be in violation of anti-kickback laws.

Nature Papers Present Ginkgo Biloba Genome Assembly, Collection of Polygenic Indexes, More

In Nature this week: a nearly complete Ginkgo biloba genome assembly, polygenic indexes for dozens of phenotypes, and more.